
Step Pharma closes $41M round to take enzyme targeting lead program into early-stage trial for T cell malignancies
The search for better T and B cell therapies have absorbed billions in R&D funds from some of the biggest drugmakers in the world. A French biotech thinks it could have a hyper-focused approach to T and B cell malignancies, and it’s taking home a decent-sized check to race to the clinic.
Step Pharma has bagged $41.5 million in funding to take its lead CTPS1 inhibitor into clinical trials for T cell malignancies by the first quarter of 2022, the French biotech said Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.